Healthcare
Live Price
Offline$29.00
+0.00% today
Window Change
-1.32%
Window
May 29, 2026 → Jun 12, 2026
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 11 bars · May 29, 2026 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Xvivo Perfusion AB (publ) (XVIPF) is a Healthcare stock with a market cap of $8.63B and listed on OTC. The stock last traded around $29.00 and down 1.3% across the available one-year price window (May 29, 2026 → Jun 12, 2026). Baseline metrics include revenue growth of -1.5%, EPS growth of -85.4%, a dividend yield of 0.0%. What stands out right now is revenue -1.5%, EPS -85.4%, free cash flow -100.0% with operating margin 11.8% and ROIC 3.3%. Valuation already assumes a fairly strong business story at P/E 116.9 and price/sales 10.3. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines XVIPF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
XVIPF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
XVIPF Max Drawdown
-1.32%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for XVIPF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$258.4M
-37.8% YoY
FY Net Income
$8.2M
-55.8% YoY
Free Cash Flow
-$106.1M
-3.0% YoY
Revenue Growth
-1.5%
EPS Growth
-85.4%
Gross Margin
65.2%
Net Margin
8.9%
Income statement
SEK
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 810M | 822M | 598M | 415M | 258M |
| Gross Profit | 532M | 616M | 445M | 297M | 188M |
| Operating Income | 93M | 88M | 4M | 6M | -18M |
| EBITDA | 153M | 289M | 81M | 39M | 39M |
| Net Income | 25M | 172M | 92M | 18M | 8M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
SEK
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 291M | 416M | 546M | 247M | 399M |
| Total Assets | 2.4B | 2.4B | 2.2B | 1.7B | 1.5B |
| Total Liabilities | 260M | 246M | 251M | 303M | 257M |
| Shareholder Equity | 2.1B | 2.2B | 1.9B | 1.4B | 1.3B |
| Total Debt | 237M | 34M | 31M | 10M | 6M |
| Net Debt | -54M | -381M | -514M | -237M | -393M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
12M
-143.3% YoY
Capital Expenditures
94M
+28.2% YoY
Free Cash Flow
106M
-3.0% YoY
Key ratios
Gross Margin
65.2%
Operating Margin
11.8%
Net Margin
8.9%
ROE
3.5%
Debt / Equity
0.06x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.